Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen’s | Enterpreneurship

Want create site? Find Free WordPress Themes and plugins.

Want create site? Find Free WordPress Themes and plugins.

A Pharmaceutical migraine-prevention has won approval, the second therapy in this new class to receive the regulatory nod this year.

The Friday approval for the Teva (NYSE: TEVA) drug fremanezumab (Ajovy) came a little earlier than expected; the target date for the FDA decision was Sept. 16. The drug is part of class of drugs called calcitonin gene-related peptides (CGRP). These antibody drugs work by blocking the CGRP protein, which is associated with migraine pain. The Amgen (NASDAQ: AMGN) CGRP drug erenumab (Aimovig) was approved in May.

Amgen’s migraine drug is a once-monthly… Read more »

UNDERWRITERS AND PARTNERS

Did you find apk for android? You can find new Free Android Games and apps.
Did you find apk for android? You can find new Free Android Games and apps.

You might also like More from author

Leave A Reply

Your email address will not be published.